Comfort in Whole-Body MRI Testing May Ease Anxiety in LFS Population

Commentary
Video

Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.

Feedback from families indicates a need to make whole-body MRI testing for Li-Fraumeni Syndrome (LFS)–associated cancers less anxiety-provoking with a greater emphasis on comfort, according to Lisa J. States, MD.

CancerNetwork® spoke with States, chair of the “Early Detection and Screening: Radiology” session at the 7th Annual LFS Association (LFSA) Symposium, about what she hopes colleagues and conference attendees will take away from the presentations highlighted at the symposium.

States, a professor of Clinical Radiology at Perelman School of Medicine at the University of Pennsylvania, as well as director of the Section of Oncologic Imaging and the endowed chair in Molecular Imaging at Children’s Hospital of Philadelphia, began by expressing a hope that colleagues will see that experts are working hard to ensure accurate MRI testing of patients with LFS to detect cancers. She followed up by highlighting a sentiment disclosed by families of patients who may express anxiety related to MRI testing.

According to States, the psychosocial aspect of undergoing a scan is a big focus in the field. She concluded by emphasizing an initiative within the field to help mitigate anxiety expressed by both pediatric and adult patients and their families by increasing the comfortability of testing.

Transcript:

What I would love for [colleagues] to take away is that we are working hard to make sure that we are as accurate as possible. We did have some feedback from families that was helpful. We will work a bit harder to make these tests less anxiety-provoking and maybe a bit more comfortable, especially for adults. We work hard with pediatrics to make these tests comfortable and make them a bit easier. But what we realized at this session is that the adults need help with that too. That is one of our big focuses: the psychosocial aspects of getting a scan. We can work on that.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Related Content